Intelligent Bio Solutions Inc. (INBS)
INBSNASDAQ-CMMedical/Dental Instruments
$2.25
-0.0400 (-1.75%) today
At the close, Nov 10, 4:00 PM ET. After hours $2.21 -1.78%
- Market cap
- $7.46m
- P/E
- –
- EPS, last 4 quarters
- $-9.02
- Dividend yield
- –
- Day range
- $2.20 to $2.30
- 52-week range
- $1.35 to $24.90
- Average volume
- 143.0k
- Previous close
- $2.29
Earnings
Next report Nov 11, 2026
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.11m | $897.0k | $1.06m | $1.82m |
| Gross profit | $518.0k | $460.0k | $535.0k | $1.21m |
| Operating income | -$3.00m | -$2.64m | -$3.00m | -$3.97m |
| Net income | -$2.98m | -$2.68m | -$2.86m | -$3.91m |
Last four quarters: revenue $4.89m, margin -254.0%, free cash flow –
News
8 latest- Intelligent Bio Solutions Inc. Q1 Loss Decreases RTTNews · 8 hours ago
- Intelligent Bio Solutions Seeks FDA Clearance For Fingerprint-Based Drug Screening System RTTNews · Sep 9, 2026
- Intelligent Bio Solutions Secures $5M Funding As Drug Screening System Nears FDA Filing RTTNews · Sep 1, 2026
- Intelligent Bio's Q2 Loss Widens As FDA Application Planned For Year-End; Stock Down RTTNews · Aug 19, 2026
- Intelligent Bio Solutions Secures ISO Recertification, Aligning With New FDA QMSR RTTNews · Aug 18, 2026
- Intelligent Bio Completes Final Clinical Study For FDA Clearance Of Codeine Screening System RTTNews · Aug 11, 2026
- Intelligent Bio Solutions Completes Precision Testing For FDA Submission RTTNews · Jul 22, 2026
- Intelligent Bio Initiates Clinical Study In Fingerprint Drug Screening For Codeine RTTNews · Jun 16, 2026
The company
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Companys current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- ibs.inc
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.